Clinical trials: Bone Marrow
Myelofibrosis
A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vismodegib plus (+) ruxolitinib versus placebo + ruxolitinib in participants with intermediate- or high-risk MF.
- Trial name
- NCT02593760
- Testing
- Ruxolitinib, Vismodegib
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 10 people
- Sponsor
- Hoffmann-La Roche
Myelofibrosis, Chronic Myelomonocytic Leukemia
Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
This multicenter, multi-arm trial evaluated the safety and efficacy of tagraxofusp, a cell division cycle protein 123 homolog-targeted therapy, in participants with either CMML or MF.
- Trial name
- NCT02268253
- Testing
- Tagraxofusp Injection
- Where
- 24 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- Stemline Therapeutics, Inc.
Myelodysplastic Syndrome (MDS)
A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome
The primary objective of the study is to determine the response rate according to the International Working Group Response criteria for the combination of FF-10501-01 and azacitidine in patients previously untreated with…
- Trial name
- NCT03486353
- Testing
- FF-10501-01, Azacitidine
- Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
Myelodysplastic Syndrome (MDS)
LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)
This study assessed the efficacy and safety of LBH589 as single agent and in combination with ESA in red blood cell transfusion-dependent Low and Int-1 MDS patients being either refractory to ESA or with a low probability of…
- Trial name
- GEPARD (NCT01034657)
- Testing
- LBH589, Epoetin Alfa
- Where
- 12 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Myelofibrosis
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.
- Trial name
- NCT00724334
- Testing
- SAR302503 (TG101348)
- Where
- 6 sites in United States
- Volunteers
- 43 people
- Sponsor
- Bristol-Myers Squibb
Cancer, Hematologic Malignancies
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone disease from multiple myeloma.
- Conditions
- Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology
- Trial name
- NCT01345019
- Testing
- Denosumab, Zoledronic acid, Denosumab (for the open-label treatment phase)
- Where
- 309 sites in United States, Australia and 27 more
- Volunteers
- 1,718 people
- Sponsor
- Amgen
Myelofibroses
TP-3654 Food Effect Study
This clinical trial will determine the bioavailability and effect of food on TP-3654 in healthy adult participants.
- Trial name
- NCT07492355
- Testing
- TP-3654
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
Bone Marrow Transplantation
An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of Ronacaleret in Healthy Human Volunteers
Ronacaleret is an orally administered CaSR antagonist which has previously been demonstrated to transiently increase PTH in both animals and humans.
- Trial name
- NCT01466335
- Testing
- Ronacaleret (100mg tablet)
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
The purpose of this randomized, two-arm, open-label expansion phase study was to collect preliminary efficacy data of panobinostat at the recommended phase II dose (RPIID) level in combination with azacytidine (5-Aza) versus an…
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT00946647
- Testing
- Panobinostat (LBH589), 5-Azacytidine
- Where
- 38 sites in United States, Austria and 12 more
- Volunteers
- 113 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator selected Tyrosine Kinase Inhibitor (TKI) for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP.
- Trial name
- NCT04971226
- Testing
- Imatinib, Nilotinib, Bosutinib
- Where
- 110 sites in United States, Australia and 27 more
- Volunteers
- 405 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoid Leukemia, Acute Myeloid Leukemia
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.
- Conditions
- Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts, Solid Tumors
- Trial name
- NCT01461538
- Testing
- brentuximab vedotin
- Where
- 29 sites in United States
- Volunteers
- 84 people
- Sponsor
- Seagen Inc.
Thrombocythemia, Myeloproliferative Disease
Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet Depletions
Multicenter, Retrospective Data Collection of Routine Clinical Use with the Spectra Optia® Apheresis System for Platelet Depletion Procedures.
- Conditions
- Thrombocythemia, Myeloproliferative Disease, Thrombocytosis
- Trial name
- PLTD (NCT02308787)
- Testing
- Spectra Optia Apheresis System
- Where
- 2 sites in Denmark, Hungary
- Volunteers
- 12 people
- Sponsor
- Terumo BCT
Chronic Myeloid Leukemia
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
To evaluate the safety and efficacy of subcutaneous administration of omacetaxine mepesuccinate (HHT) in achieving a clinical response in CML patients in chronic, accelerated, or blast phase who have failed prior imatinib therapy…
- Trial name
- NCT00375219
- Testing
- Omacetaxine mepesuccinate
- Where
- 32 sites in United States, Canada and 8 more
- Volunteers
- 103 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Paroxysmal Nocturnal Hemoglobinuria
Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
A study to assess the safety and efficacy of eculizumab in Japanese patients with hemolytic PNH.
- Trial name
- NCT01192399
- Testing
- Eculizumab
- Volunteers
- 29 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Myelodysplastic Syndromes(MDS)
Collection of Samples From Patients With MDS
The purpose of this study is to collect information and bone marrow, blood, saliva, cheek cells and skin to be used in the laboratory to assist the sponsor in identifying a new way of treating MDS.
- Trial name
- NCT03072498
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- PersImmune, Inc
Osteoporosis, Osteoarthritis
OSTEOMICS: Identifying Regulators of Bone Homeostasis
Diseases of bone associated with ageing, including osteoporosis (OP) and osteoarthritis (OA), reduce bone mass, bone strength and joint integrity.
- Conditions
- Osteoporosis, Osteoarthritis, Bone Diseases, Bone Fracture
- Trial name
- OSTEOMICS (NCT05732870)
- Testing
- Relevant orthopaedic surgery
- Where
- 8 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Relation Therapeutics
Multiple Myeloma
Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma
The purpose of this research study is to test the safety and effectiveness of replacing vincristine with a drug called bortezomib (also known as "Velcade"or PS341) in the standard therapy vincristine, doxorubicin (not limited to…
- Trial name
- NCT00441168
- Testing
- adriamycin, bortezomib, dexamethasone
- Where
- 16 sites in Croatia, Germany and 5 more
- Volunteers
- 30 people
- Sponsor
- Janssen-Cilag International NV
Polycythemia Vera (PV), Myelofibrosis (MF)
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and…
- Conditions
- Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis
- Trial name
- NCT07469891
- Testing
- PRT12396
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 100 people
- Sponsor
- Prelude Therapeutics Incorporated
Amyotrophic Lateral Sclerosis
Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis
A Phase I, single center, prospective, non-randomized, open label, safety/efficacy study of the infusion of autologous bone marrow-derived stem cells, in 6 patients with Amyotrophic Lateral Sclerosis according to established…
- Trial name
- ALS (NCT01082653)
- Testing
- autologous bone marrow-derived stem cells
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- TCA Cellular Therapy
Ventricular Dysfunction, Myocardial Infarction
Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone
The object of this open-labeled, uncontrolled pilot study was to investigate the safety and feasibility of percutaneously transplanting autologous bone marrow (ABM) cells into the myocardium using the helical needle…
- Trial name
- TABMMI (NCT00507468)
- Testing
- Transendocaridal Transplantation of Autologous Bone Marrow
- Where
- 2 sites in Argentina
- Volunteers
- 20 people
- Sponsor
- BioCardia, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.